← Back to Search

Short Chain Fatty Acid

Ca-Mg Butyrate for Gulf War Syndrome (Butyrate Trial)

Phase 2
Recruiting
Led By Saurabh Chatterjee, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Defined rheumatologic inflammatory disorders
Immunosuppressive drugs or biologic response modifiers within 3 months of study entry
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline at 3, 6, 9, 12, 18 and 20 weeks

Summary

This trial is looking to see if a treatment consisting of butyric acid calcium and magnesium derivatives (Ca-Mg Butyrate) can improve the physical function of Veterans suffering from Gulf War Illness (GWI), as measured by the Short Form Health Survey 36-item (VSF-36). The trial will also focus on the drug's role in restoring gut microbiome and virome, decreasing gastrointestinal disturbances, chronic fatigue, systemic inflammation, and cognitive deficits.

Who is the study for?
This trial is for Gulf War era veterans aged between 40 and 70 who suffer from moderate to severe GWI, as defined by CDC and Kansas criteria. Participants must score less than 30 on the VSF36 physical domain, with no other health conditions that could explain their symptoms.
What is being tested?
The trial tests if Ca-Mg Butyrate improves physical function in those with GWI. It measures changes in physical functioning via the VSF-36 survey and examines effects on gut microbiome, gastrointestinal issues, chronic fatigue, inflammation, and cognitive deficits.
What are the potential side effects?
Potential side effects are not explicitly listed but may include digestive disturbances or allergic reactions related to butyrate supplements or their derivatives.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a diagnosed inflammatory disorder.
Select...
I haven't taken immunosuppressive drugs or biologics in the last 3 months.
Select...
I have bipolar disorder and have not received treatment for it.
Select...
My organs are functioning properly.
Select...
I have had an organ transplant.
Select...
I haven't taken medications affecting my gut, pain, or immune system in the last 3 months.
Select...
I have schizophrenia that has not been treated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline at 3, 6, 9, 12, 18 and 20 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline at 3, 6, 9, 12, 18 and 20 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Veterans Short Form 36-Item Health Survey Physical Component Summary
Secondary study objectives
California Verbal Learning Test (CVLT-II)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cal-Mag-ButyrateExperimental Treatment1 Intervention
Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.
Group II: Placebo for Cal-Mag-ButyratePlacebo Group1 Intervention
Take oral capsule as directed (600 mg, twice a day for 18 weeks) with or without food.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,668 Previous Clinical Trials
3,765,746 Total Patients Enrolled
Miami VA Healthcare SystemFED
17 Previous Clinical Trials
2,287 Total Patients Enrolled
VA Salt Lake City Health Care SystemFED
24 Previous Clinical Trials
261,943 Total Patients Enrolled
Saurabh Chatterjee, PhDPrincipal InvestigatorVA Long Beach Healthcare System, Long Beach, CA

Media Library

Ca-Mg Butyrate (Short Chain Fatty Acid) Clinical Trial Eligibility Overview. Trial Name: NCT05367245 — Phase 2
Cognitive Impairment Research Study Groups: Cal-Mag-Butyrate, Placebo for Cal-Mag-Butyrate
Cognitive Impairment Clinical Trial 2023: Ca-Mg Butyrate Highlights & Side Effects. Trial Name: NCT05367245 — Phase 2
Ca-Mg Butyrate (Short Chain Fatty Acid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05367245 — Phase 2
~0 spots leftby Jan 2025